CU6 12.1% $7.67 clarity pharmaceuticals ltd

Ann: First patient dosed in Phase III prostate cancer trial, page-4

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,584 Posts.
    lightbulb Created with Sketch. 396
    Nice to see what happens in a biotech when they actually get trials underway and patients dosed.
 
watchlist Created with Sketch. Add CU6 (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.